This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Glaxo (GSK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven fourth-quarter sales. The performance of vaccines during Q4 remains to be seen.
GlaxoSmithKline (GSK) Stock Moves -1.71%: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $44.92, moving -1.71% from the previous trading session.
Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges
by Zacks Equity Research
Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.25, marking a -1.07% move from the previous day.
Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA
by Zacks Equity Research
Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.
Glaxo's (GSK) New Drugs Drive Sales Amid Rising Competition
by Zacks Equity Research
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.
SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study
by Zacks Equity Research
Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.10, marking a +0.49% move from the previous day.
Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE
by Kinjel Shah
Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.
J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $44.88, moving -1.77% from the previous trading session.
Glaxo (GSK) Stock Down As Unilever Decides Not to Raise Offer
by Zacks Equity Research
Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.
Glaxo (GSK) Rejects Unilever's $68B Bid for Consumer Business
by Zacks Equity Research
Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.
The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo
by Zacks Equity Research
Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.
Glaxo (GSK), Vir Seek EUA for Intramuscular Sotrovimab in US
by Zacks Equity Research
Glaxo (GSK) and Vir are looking to get authorization for the intramuscular administration of their COVID-19 drug candidate, sotrovimab, which is currently authorized for intravenous administration.
Pharma Stock Roundup: PFE's Research Deal With BEAM & Other Updates
by Kinjel Shah
Pfizer (PFE) inks research collaboration with Beam Therapeutics. Merck's (MRK) Keytruda improves survival in adjuvant lung cancer
GlaxoSmithKline (GSK) Stock Moves -0.4%: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.06, marking a -0.4% move from the previous day.
Glaxo (GSK) & Vir to Supply More COVID Antibody Doses in US
by Zacks Equity Research
The U.S. government enters into an agreement with Glaxo (GSK) and Vir Biotechnology (VIR) to procure an additional 600,000 doses of sotrovimab for early treatment of COVID-19.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $45.04 in the latest trading session, marking a +0.45% move from the prior day.
Gilead (GILD) Partners With Merck for Keytruda in NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Merck collaborate to evaluate the former's breast cancer drug in combination with the latter's blockbuster drug Keytruda for NSCLC study.
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $43.60 in the latest trading session, marking a +0.14% move from the prior day.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $43.54 in the latest trading session, marking a -0.3% move from the prior day.
Spero (SPRO) Application for UTI Drug Gets Priority Review
by Zacks Equity Research
Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.
Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug
by Zacks Equity Research
Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.